Capmatinib (Tabrecta) is a highly selective MET inhibitor that has demonstrated significant efficacy in patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations.

What Are the Purchase Channels for Capmatinib (Tabrecta)?

Overseas Purchase

Patients may choose to consult and purchase the medication at hospital pharmacies or licensed drugstores in countries/regions where capmatinib has been approved for marketing.

Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make a budget and plan in advance before purchasing.

Purchase via Medical Service Institutions

Patients can consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.

These institutions usually provide legal import channels, along with professional consultation and guidance services.

Precautions for Purchasing Capmatinib (Tabrecta)

Professional Testing

Prior to the administration of capmatinib, professional testing for MET exon 14 skipping mutations must be performed to confirm the presence of applicable mutation types.

This medication is specifically indicated for the treatment of patients with non-small cell lung cancer confirmed to be positive for MET exon 14 skipping mutations through testing.

Vigilance Against Drug Interactions

Concomitant use of capmatinib with strong or moderate CYP3A inducers may decrease drug exposure, thereby impairing its anti-tumor activity.

Patients must truthfully inform their physicians of all medications they are currently taking, including prescription drugs, over-the-counter drugs, vitamins, and herbal supplements.

Medication in Special Populations

Capmatinib may cause fetal harm.

Pregnant women must undergo a rigorous risk assessment before using this medication.

Women of childbearing potential and male patients should take effective contraceptive measures during treatment and for 1 week after the last dose.

Identification of Authentic Capmatinib (Tabrecta)

Verification of Physical Characteristics

Authentic capmatinib is available in two strengths: the 150 mg tablet is a pale orange-brown oval film-coated tablet, and the 200 mg tablet is a yellow oval film-coated tablet.

Carefully check whether the color, shape, and markings of the tablets are consistent with the official descriptions.

Verification of Packaging Information

Inspect whether the drug packaging is intact, the label printing is clear, and information including the drug name, strength, batch number, and expiration date is complete.

Authentic product packaging should bear clear anti-counterfeiting labels and traceability codes.

Verification via Official Channels

Check the drug’s approval number and manufacturer information through official platforms such as the National Medical Products Administration.

Capmatinib is manufactured by Novartis Pharmaceuticals Corporation; ensure that the information matches the purchased medication.